DAVID GRAHAM to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications DAVID GRAHAM has written about Randomized Controlled Trials as Topic.
Connection Strength
0.499
-
Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker-Based Dual, Triple, and Quadruple Regimens for First-Line Helicobacter pylori Infection Treatment: A Systematic Review and Network Meta-Analysis. Am J Gastroenterol. 2025 Apr 01; 120(4):787-798.
Score: 0.154
-
Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency. Clin Gastroenterol Hepatol. 2018 06; 16(6):800-808.e7.
Score: 0.095
-
Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation. Am J Med Sci. 2011 Nov; 342(5):356-64.
Score: 0.063
-
Inaccurate endoscopy: a better explanation for placebo-associated endoscopic ulcers. Aliment Pharmacol Ther. 2009 Nov 01; 30(9):955-7; author reply 957-60.
Score: 0.055
-
Risk of low-dose aspirin: emphasis on outliers undermines the credibility of the conclusions. Aliment Pharmacol Ther. 2007 Feb 01; 25(3):345-6; author reply 346-7.
Score: 0.045
-
Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology. 2021 08; 161(2):495-507.e4.
Score: 0.030
-
PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis. Helicobacter. 2020 Aug; 25(4):e12692.
Score: 0.028
-
Prevention of diarrhea caused by enterotoxigenic Escherichia coli: lessons learned with volunteers. Rev Infect Dis. 1990 Jan-Feb; 12 Suppl 1:S68-72.
Score: 0.014
-
Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009 Apr; 14(2):109-18.
Score: 0.013